Stocks · News reference
Reported Earlier: Celularity And MuseCell Innovations Expand U.S. Manufacturing Collaboration, With Potential For $300M+ In Purchases Over Five Years
Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Celularity Inc (CELU)
Filed: 2026-10-29 AccNo: 0001493152-26-049203 Size: 236 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Celularity Regains Compliance with Nasdaq Periodic Financial Reporting Requirement
Celularity Inc. announced it has received confirmation from Nasdaq that it has regained compliance with the exchange's periodic financial reporting requirements following the filing of its second-quarter 2026 Form 10-Q.
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.
Celularity Q1 EPS $0.02 Up From $(0.84) YoY, Sales $3.846M Down From $11.426M YoY
Celularity shares are trading higher after the company announced an initial closing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants.